Campbell Bunce, chief scientific officer at Abzena, revisited his 2026 industry predictions on the direction of the biologics and bioconjugate market and gives an update on ADCs.
Campbell Bunce
Advertisement
Campbell Bunce is Chief Scientific Officer at Abzena.
Articles by Campbell Bunce
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
2
Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs
3
Ask the Expert: Drug Approval Submissions
4
Everything to Know about BMS & NVidia’s AI Supercomputer
5